Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UNITED THERAPEUTICS CORPORATION

(UTHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

United Therapeutics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021

08/04/2021 | 06:05am EDT

United Therapeutics Corporation announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 446.5 million compared to USD 362 million a year ago. Operating income was USD 222.2 million compared to USD 140.5 million a year ago. Net income was USD 172.6 million compared to USD 107.1 million a year ago. Basic earnings per share from continuing operations was USD 3.85 compared to USD 2.43 a year ago. Diluted earnings per share from continuing operations was USD 3.65 compared to USD 2.41 a year ago. For the half year, total revenue was USD 825.6 million compared to USD 718.3 million a year ago. Operating income was USD 157.4 million compared to USD 307.2 million a year ago. Net income was USD 200.9 million compared to USD 244.8 million a year ago. Basic earnings per share from continuing operations was USD 4.49 compared to USD 5.56 a year ago. Diluted earnings per share from continuing operations was USD 4.28 compared to USD 5.53 a year ago.


© S&P Capital IQ 2021
All news about UNITED THERAPEUTICS CORPORATION
09/16INSIDER SELL : United Therapeutics
MT
09/15CAE : and BETA Technologies Detail Strategic Partnership For Pilot and Maintenan..
MT
09/10UNITED THERAPEUTICS : Releases its Annual Corporate Responsibility Report
PR
08/24UNITED THERAPEUTICS : to Present Tyvaso DPI™ BREEZE Clinical Data at the E..
PR
08/24United Therapeutics Corporation to Present Tyvaso Dpi™ Breeze Clinical Data A..
CI
08/20UNITED THERAPEUTICS : 2020 Annual Report
PU
08/13LIQUIDIA : U.S. Patent Trial and Trademark Appeal Board Decides to Institute Int..
AQ
08/12LIQUIDIA : Says US PTAB Initiates Review of United Therapeutics' Tyvaso Patent
MT
08/11LIQUIDIA : Reports Second Quarter 2021 Financial Results and Provides Corporate ..
AQ
08/04UPDATE : United Therapeutics Shares Jump 14% After Q2 Gains Exceed Estimates
MT
More news
Analyst Recommendations on UNITED THERAPEUTICS CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 671 M - -
Net income 2021 524 M - -
Net cash 2021 509 M - -
P/E ratio 2021 17,6x
Yield 2021 -
Capitalization 8 982 M 8 982 M -
EV / Sales 2021 5,07x
EV / Sales 2022 4,19x
Nbr of Employees 950
Free-Float 60,7%
Chart UNITED THERAPEUTICS CORPORATION
Duration : Period :
United Therapeutics Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UNITED THERAPEUTICS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 200,08 $
Average target price 231,89 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Martine A. Rothblatt Chairman & Chief Executive Officer
Michael Ian Benkowitz President & Chief Operating Officer
James Christopher Edgemond Chief Financial Officer & Treasurer
Raymond C. Kurzweil Independent Director
Louis Wade Sullivan Independent Director
Sector and Competitors
1st jan.Capi. (M$)
UNITED THERAPEUTICS CORPORATION31.81%8 982
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420